Reignwood Group
1
150M
1
0.03
- Areas of investment
Summary
Reignwood Group is the famous Corporate Investor, which was founded in 1984. The venture was found in Asia in China. The main department of described Corporate Investor is located in the Beijing.
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the Reignwood Group, startups are often financed by Carrie Cox. The meaningful sponsors for the fund in investment in the same round are Pacific Eagle Asset Management, Gavril Yushvaev, Brady Dougan. In the next rounds fund is usually obtained by California Institute for Regenerative Medicine.
For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Humacyte. Among the most successful fund investment fields, there are Biotechnology, Medical Device.
The top activity for fund was in 2015. The common things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 deals per year.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.03
- Investments by industry
- Biotechnology (1)
- Medical Device (1)
- Medical (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2015
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Avg. valuation at time of investment
- 640M
- Group Appearance index
- 1.00
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Humacyte | 20 Oct 2015 | Biotechnology, Medical Device, Medical | Early Stage Venture | 150M | United States, North Carolina |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.